Mutant-selective and pan-RAS(ON) multi-selective inhibitors have improved clinical outcomes for patients with RAS-driven cancers; however, adaptive resistance limits the depth and durability of response. Using an integrated genetic, transcriptomic, and mass-spectrometry-based quantitative temporal proteomic platform, w...
A. Padhye, Kalisa Kang, Fan-Yi Kong et al.· bioRxiv· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cell· 0 citations
Recent studies have identified a high prevalence of low grade pancreatic intraepithelial neoplasia (PanIN) in the pancreata of healthy adults. This study aimed to characterize the transcriptomic landscape of human PanINs at single cell resolution, with the goal of identifying hallmarks of initiation and progressi...
C. Nguyen, Anders W. Ohman, Winston R. Becker et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma is refractory to most therapies, including immunotherapies, where reinvigoration of CD8 T cells with immune checkpoint blockade is insufficient to induce long-term durable remissions. Direct inhibitors of KRAS are clinically promising, although acquired resistance is common. To test i...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cancer Research· 0 citations
These studies establish a comprehensive proteomic resource for the PDAC/KRASi research community and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to drive deeper, sustained responses and prevent or forestall KRASi resistance.
Jonathan M. DeLiberty, Fan-Yi Kong, Qi-Jia Yu et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
